Madison Area Lyme Support Group
Articles & Documents
Petitioning the State of Wisconsin
Biomarker for Chronic Fatigue Syndrome Identified
http://med.stanford.edu/news/all-news/2019/04/biomarker-for-chronic-fatigue-syndrome-identified.html
Stanford scientists devised a blood-based test that accurately identified people with chronic fatigue syndrome, a new study reports.
Ron Davis is the senior author of a paper that describes a blood test that may be able to identify chronic fatigue syndrome. Steve Fisch
People suffering from a debilitating and often discounted disease known as chronic fatigue syndrome may soon have something they've been seeking for decades:
scientific proof of their ailment
Researchers at the Stanford University School of Medicine have created a blood test that can flag the disease, which currently lacks a standard, reliable diagnostic test.
"Too often, this disease is categorized as imaginary," said Ron Davis, PhD, professor of biochemistry and of genetics. When individuals with chronic fatigue syndrome seek help from a doctor, they may undergo a series of tests that check liver, kidney and heart function, as well as blood and immune cell counts, Davis said. "All these different tests would normally guide the doctor toward one illness or another, but for chronic fatigue syndrome patients, the results all come back normal," he said.
The problem, he said, is that they're not looking deep enough. Now, Davis; Rahim Esfandyarpour, PhD, a former Stanford research associate; and their colleagues have devised a blood-based test that successfully identified participants in a study with chronic fatigue syndrome. The test, which is still in a pilot phase, is based on how a person's immune cells respond to stress. With blood samples from 40 people — 20 with chronic fatigue syndrome and 20 without — the test yielded precise results, accurately flagging all chronic fatigue syndrome patients and none of the healthy individuals.
The diagnostic platform could even help identify possible drugs to treat chronic fatigue syndrome. By exposing the participants' blood samples to drug candidates and rerunning the diagnostic test, the scientists could potentially see whether the drug improved the immune cells' response. Already, the team is using the platform to screen for potential drugs they hope can help people with chronic fatigue syndrome down the line.
A paper describing the research findings was published online April 29 in the Proceedings of the National Academy of Sciences. Davis is the senior author. Esfandyarpour, who is now on the faculty of the University of California-Irvine, is the lead author.
Providing the proof
The diagnosis of chronic fatigue syndrome, when it actually is diagnosed, is based on symptoms — exhaustion, sensitivity to light and unexplained pain, among other things — and it comes only after other disease possibilities have been eliminated. It is also known as myalgic encephalomyelitis and designated by the acronym ME/CFS.
It's estimated that 2 million people in the United States have chronic fatigue syndrome, but that's a rough guess, Davis said, and it's likely much higher.
For Davis, the quest to find scientific evidence of the malady is personal. It comes from a desire to help his son, who has suffered from ME/CFS for about a decade. In fact, it was a biological clue that Davis first spotted in his son that led him and Esfandyarpour to develop the new diagnostic tool.
We clearly see a difference in the way healthy and chronic fatigue syndrome immune cells process stress.
The approach, of which Esfandyarpour led the development, employs a "nanoelectronic assay," which is a test that measures changes in miniscule amounts of energy as a proxy for the health of immune cells and blood plasma. The diagnostic technology contains thousands of electrodes that create an electrical current, as well as chambers to hold simplified blood samples composed of immune cells and plasma. Inside the chambers, the immune cells and plasma interfere with the current, changing its flow from one end to another. The change in electrical activity is directly correlated with the health of the sample.
The idea is to stress the samples from both healthy and ill patients using salt, and then compare how each sample affects the flow of the electrical current. Changes in the current indicate changes in the cell: the bigger the change in current, the bigger the change on a cellular level. A big change is not a good thing; it's a sign that the cells and plasma are flailing under stress and incapable of processing it properly. All of the blood samples from ME/CFS patients created a clear spike in the test, whereas those from healthy controls returned data that was on a relatively even keel.
"We don't know exactly why the cells and plasma are acting this way, or even what they're doing," Davis said. "But there is scientific evidence that this disease is not a fabrication of a patient's mind. We clearly see a difference in the way healthy and chronic fatigue syndrome immune cells process stress."
Now, Esfandyarpour and Davis are expanding their work to confirm the findings in a larger cohort of participants. Recruitment for the larger project, which aims to further confirm the success of the diagnostic test, is being done on a rolling basis. Those who are interested in participating should contact clinical research coordinator Anna Okumu.
Doubling up
In addition to diagnosing ME/CFS, the researchers are also harnessing the platform to screen for drug-based treatments, since currently the options are slim.
"Using the nanoelectronics assay, we can add controlled doses of many different potentially therapeutic drugs to the patient's blood samples and run the diagnostic test again," Esfandyarpour said.
If the blood samples taken from those with ME/CFS still respond poorly to stress and generate a spike in electrical current, then the drug likely didn't work. If, however, a drug seems to mitigate the jump in electrical activity, that could mean it is helping the immune cells and plasma better process stress. So far, the team has already found a candidate drug that seems to restore healthy function to immune cells and plasma when tested in the assay. The drug, while successful in the assay, is not currently being used in people with ME/CFS, but Davis and Esfandyarpour are hopeful that they can test their finding in a clinical trial in the future.
All of the drugs being tested are either already approved by the Food and Drug Administration or will soon be broadly accessible to the public, which is key to fast access and dissemination should any of these compounds pan out.
Davis is a member of Stanford Bio-X, the Stanford Cancer Institute and the Stanford Maternal & Child Health Research Institute.
Other Stanford authors of the study are research scientists Neda Nemat-Gorgani and Julie Wilhelmy and research assistant, Alex Kashi.
The study was funded by the Open Medicine Foundation. Davis is the director of the foundation's scientific advisory board.
Stanford's departments of Genetics and of Biochemistry also supported the work.
By HANAE ARMITAGE
Hanae Armitage is a science writer for the medical school's Office of Communication & Public Affairs. Email her at harmitag@stanford.edu.
**Comment**
A few things stick out:
This researcher, like those doing the heavy lifting in the Lyme/MSIDS world, are personally vested. They find things because this is more than a job to them. They NEED answers for either themselves or their loved ones.
"Not Looking deep enough," is a problem in the Lyme/MSIDS world as well. Look deeper!
Due to this man's work, some patients are finally going to be taken seriously. This is HUGE.
Notice that ME/CFS is a clinical diagnosis just like Lyme/MSIDS. Because testing is so poor or doesn't exist, patients aren't believed due to a number or lack of a number on paper.
I have to think that "eliminating other disease possibilities" is the fly in the ointment with ME/CFS. How can you eliminate Lyme/MSIDS when doctors can't find it to begin with and they aren't willing to look deeper?
Activism, research, Testing
Comments Off on Biomarker for Chronic Fatigue Syndrome Identified
Data Shows Lyme Disease Has Increased – Even in Areas That Aren't Endemic
When Lyme Disease Doesn't Go Away
Archives Select Month January 2020 (69) December 2019 (113) November 2019 (106) October 2019 (39) September 2019 (35) August 2019 (108) July 2019 (117) June 2019 (109) May 2019 (120) April 2019 (111) March 2019 (106) February 2019 (62) January 2019 (84) December 2018 (59) November 2018 (58) October 2018 (90) September 2018 (82) August 2018 (71) July 2018 (63) June 2018 (83) May 2018 (85) April 2018 (68) March 2018 (82) February 2018 (77) January 2018 (41) December 2017 (39) November 2017 (38) October 2017 (53) September 2017 (56) August 2017 (53) July 2017 (49) June 2017 (51) May 2017 (32) April 2017 (37) March 2017 (49) February 2017 (23) January 2017 (38) December 2016 (36) November 2016 (41) October 2016 (21) September 2016 (15) August 2016 (7) July 2016 (19) June 2016 (16) May 2016 (15) April 2016 (15) March 2016 (15) February 2016 (21) January 2016 (10) December 2015 (6) November 2015 (8) October 2015 (10) September 2015 (8) August 2015 (9) July 2015 (10) June 2015 (4) May 2015 (4) April 2015 (4) March 2015 (4) February 2015 (3) December 2014 (3) November 2014 (1) October 2014 (2) September 2014 (5) August 2014 (2) July 2014 (1) May 2014 (2) March 2014 (2) January 2014 (1) November 2013 (1) October 2013 (1) September 2013 (1) August 2013 (3) July 2013 (3) April 2013 (1) March 2013 (1) January 2013 (1) December 2012 (1) November 2012 (1) October 2012 (2) September 2012 (1) August 2012 (1) July 2012 (4) June 2012 (2) May 2012 (1) April 2012 (1) March 2012 (3) February 2012 (1) January 2012 (1) December 2011 (1) November 2011 (1) October 2011 (2) September 2011 (9) June 2011 (1) May 2011 (3) April 2011 (1) March 2011 (4) January 2011 (1) December 2010 (1) October 2010 (3) September 2010 (3) August 2010 (7) July 2010 (2) June 2010 (2) May 2010 (7)
Lyme Non-Profits
Wisconsin Lyme Network Facebook
Lyme Resources
Affordable Blood Draws/injections in Wisconsin
Blood Draws in Madison
Columbia Specimen Bank 646-774-7503
Find a Lyme Support Group
IgenX, Inc. (lab testing)
ILADS (International Lyme And Associated Diseases Society)
Learn about Lyme
Lyme Bio Bank (NDRI & Bay Area Lyme Foundation)
Lyme Curriculum & Educational Activities
Lyme Disease Association
Lyme Info
Lyme-Symptoms
Lymedisease.org (Formally CALDA)
LymeLight Foundation
National Suicide Hotline
On-line Mental Health Therapy
SE Wisconsin Support Group
Tick borne disease education
Tick Borne Disease Prevention: Stuff for Kids
Tick-Borne Disease Alliance
TRUTHCURES
What is Lyme
WISCONSIN LYME NETWORK
Lyme Support Group of Southeast Wisconsin (Facebook)
Military Lyme Info
Military Lyme Support (Facebook)
Parents Whose Children Have Lyme/MSIDS
Wisconsin-LymeSupport (Yahoo Group)
Wisconsin/Illinios Lyme (Facebook)
Good News For Bartonella Patients: Identification of FDA-Approved Drugs With Higher Activity Than Current Front-line Drugs
Psychosis and PANS Meet Plasmapheresis - Our Final Slam Dunk
Babesia Treatment
Bill Gates' Former Doctor Says Billionaire 'Refused to Vaccinate His Children'
Palsy of the Gut & Other GI Manifestations of Lyme/MSIDS
If Disulfiram is the Cure for Lyme Disease, Should it Be Prescribed to All Lyme Disease Patients?
MCAS - Triggers, Symptoms & How to Cope
DMSO/MSM for Lyme/MSIDS
Mast Cell Activation Syndrome & Lyme/MSIDS
Alpha Gal Meat Allergy
Anaplasmosis Treatment
Bartonella Treatment
Borrelia Miyamotoi (Relapsing Fever Group)
C-diff
Chiropractic Care for MSIDS
Educational handouts
Ehrlichiosis Treatment
Heart Issues
Lyme Disease Treatment
Lyme Vaccine
Morgellons
Mycoplasma Treatment
Parasite Treatment
Support Group Presentations
Tickborne Relapsing Fever